M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 12.04 PLN 1.35% Market Closed
Market Cap: 194.6m PLN
Have any thoughts about
Mabion SA?
Write Note

Mabion SA
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mabion SA
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
M
Mabion SA
WSE:MAB
Retained Earnings
-zł109.7m
CAGR 3-Years
21%
CAGR 5-Years
1%
CAGR 10-Years
-42%
R
Read Gene SA
WSE:RDG
Retained Earnings
zł906.1k
CAGR 3-Years
-37%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
G
Genomed SA
WSE:GEN
Retained Earnings
zł2.2m
CAGR 3-Years
39%
CAGR 5-Years
8%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Retained Earnings
-zł1.1B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
-8%
U
Urteste SA
WSE:URT
Retained Earnings
-zł8.4m
CAGR 3-Years
-91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Retained Earnings
zł94.1m
CAGR 3-Years
31%
CAGR 5-Years
48%
CAGR 10-Years
6%
No Stocks Found

Mabion SA
Glance View

Market Cap
194.6m PLN
Industry
Biotechnology

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

MAB Intrinsic Value
13.91 PLN
Undervaluation 13%
Intrinsic Value
Price
M

See Also

What is Mabion SA's Retained Earnings?
Retained Earnings
-109.7m PLN

Based on the financial report for Sep 30, 2024, Mabion SA's Retained Earnings amounts to -109.7m PLN.

What is Mabion SA's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-42%

Over the last year, the Retained Earnings growth was 9%. The average annual Retained Earnings growth rates for Mabion SA have been 21% over the past three years , 1% over the past five years , and -42% over the past ten years .

Back to Top